Cambridge, USA-based gene therapy company Sarepta Therapeutics has released positive data from multiple studies investigating its Duchenne muscular dystrophy (D 7 July 2022
Breakups can be messy, but 18 months after the UK formally left the European Union, the newly-empowered Medicines and Healthcare products Regulatory Agency (MHR 26 June 2022
A major early-stage win in large B-cell lymphoma (LBCL) will take some pressure off the architects of AbbVie’s $750 million bet on Danish biotech Genmab. 14 June 2022
Vertex Pharmaceuticals and CRISPR Therapeutics have presented new data on exa-cel at the European Hematology Association (EHA) annual meeting. 13 June 2022
At the annual meeting of the American Headache Society (AHS), central nervous system specialist Impel Pharmaceuticals is to outline one oral presentation and th 10 June 2022
Dostarlimab, an anti–PD-1 monoclonal antibody marketed by GSK under the brand name Jemperli, has shown impressive results in mismatch repair–deficient stage II 7 June 2022
Even as generic competition gathers, the treatment landscape in multiple myeloma will likely be dominated by Bristol Myers Squibb’s Revlimid (lenalidomide) for 7 June 2022
The Johnson & Johnson subsidiary Janssen has presented data in multiple myeloma and mantle cell lymphoma at the 2022 American Society of Clinical Oncology (ASCO 6 June 2022
Bristol Myers Squibb has presented two lots of data on its immunotherapy combination of Opdivo (nivolumab)plus Yervoy (ipilimumab) at the 2022 American Society 6 June 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.